Michelle Smolenaars Hunter
Michelle Smolenaars Hunter is a spokesperson for GSK, the pharmaceutical company developing gepotidacin, a promising new antibiotic for treating gonorrhea. She has announced plans for a U.S. regulatory submission for gepotidacin's use against uncomplicated gonorrhea, reflecting the company's commitment to addressing the urgent need for effective treatments amid rising antibiotic resistance.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 7.00 | 0.06% | +0% | 38,005,238 | 22,277 | $1,700,000 | 996$ |
| Totals | 1 | 38,005,238 | 22,277 | $1,700,000 | 996$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Michelle Smolenaars Hunter is a spokesperson for GSK who stated that the company plans to file a U.S. regulatory submission for gepotidacin.
7